This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA) and Amgen (AMGN)

Tipranks - Tipranks - Tue Jun 16, 4:12PM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neumora Therapeutics, Inc. (NMRA) and Amgen (AMGN).

Claim 55% Off TipRanks

Neumora Therapeutics, Inc. (NMRA)

Needham analyst Ami Fadia reiterated a Buy rating on Neumora Therapeutics, Inc. today and set a price target of $5.00. The company’s shares closed last Monday at $0.91.

According to TipRanks.com, Fadia is a 5-star analyst with an average return of 29.7% and a 56.0% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, MapLight Therapeutics, Inc., and Praxis Precision Medicines. ;'>

Currently, the analyst consensus on Neumora Therapeutics, Inc. is a Moderate Buy with an average price target of $8.83, implying an 849.3% upside from current levels. In a report issued on June 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.

See the top stocks recommended by analysts >>

Amgen (AMGN)

Mizuho Securities analyst Salim Syed maintained a Hold rating on Amgen today and set a price target of $303.00. The company’s shares closed last Monday at $350.53.

According to TipRanks.com, Syed is a 1-star analyst with an average return of -0.9% and a 42.6% success rate. Syed covers the Healthcare sector, focusing on stocks such as Maze Therapeutics, Inc., Syndax Pharmaceuticals, and Atara Biotherapeutics. ;'>

Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $357.38, implying a 0.5% upside from current levels. In a report issued on June 1, Bernstein also maintained a Hold rating on the stock.

Read More on NMRA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).